iCAD (NASDAQ:ICAD) had its price objective raised by Craig Hallum from $9.00 to $15.00 in a report published on Thursday morning, The Fly reports. Craig Hallum currently has a buy rating on the technology company’s stock.

Several other brokerages also recently issued reports on ICAD. Dougherty & Co assumed coverage on iCAD in a report on Friday, December 20th. They set a buy rating and a $10.00 price target for the company. Lake Street Capital assumed coverage on iCAD in a report on Thursday, January 9th. They set a buy rating and a $14.00 target price for the company. Finally, JMP Securities assumed coverage on iCAD in a report on Wednesday, February 5th. They set an outperform rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $13.50.

iCAD stock traded up $0.22 during mid-day trading on Thursday, hitting $11.98. 525,000 shares of the company’s stock traded hands, compared to its average volume of 224,138. The firm has a 50 day simple moving average of $8.77 and a two-hundred day simple moving average of $7.34. iCAD has a fifty-two week low of $4.05 and a fifty-two week high of $12.32. The stock has a market cap of $226.29 million, a price-to-earnings ratio of -15.56 and a beta of 1.09. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.76 and a quick ratio of 1.62.

Institutional investors and hedge funds have recently bought and sold shares of the company. Cadence Capital Management LLC acquired a new stake in shares of iCAD during the third quarter worth $73,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of iCAD during the fourth quarter worth $80,000. Virtu Financial LLC acquired a new stake in shares of iCAD during the third quarter worth $106,000. California Public Employees Retirement System lifted its holdings in shares of iCAD by 3.6% during the fourth quarter. California Public Employees Retirement System now owns 34,271 shares of the technology company’s stock worth $266,000 after buying an additional 1,200 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of iCAD during the fourth quarter worth $391,000. 25.46% of the stock is owned by institutional investors.

iCAD Company Profile

iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.

Featured Story: S&P 500 Index

The Fly

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.